Wednesday, July 8, 2026

pharma · Parkinson Disease · Tuberculosis · GANX

Gain Therapeutics

Gain Therapeutics clinical programs — 1 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Bethesda, USA HQ
2017 Founded
28 Employees
Public company Type
GANX · NYSE Ticker
Company details
Status
Public
HQ
Bethesda, USA
Founded
2017
Employees
28
Programs
4
Drugs
7
Patents
27
Intelligence · Clinical Programs

Gain Therapeutics projects

1 ClinicalTrials.gov programs sponsored by Gain Therapeutics.

Gain Therapeutics has 1 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. GT-02287

    Gain Therapeutics

    Parkinson Disease

    phase 1 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Gain Therapeutics have?

1 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.